| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 815 | 2018 |
| Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants F Pareja, FC Geyer, C Marchiò, KA Burke, B Weigelt, JS Reis-Filho NPJ breast cancer 2 (1), 1-11, 2016 | 169 | 2016 |
| The spectrum of triple-negative breast disease: high-and low-grade lesions FC Geyer, F Pareja, B Weigelt, E Rakha, IO Ellis, SJ Schnitt, JS Reis-Filho The American journal of pathology 187 (10), 2139-2151, 2017 | 165 | 2017 |
| Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR DA Ferraro, N Gaborit, R Maron, H Cohen-Dvashi, Z Porat, F Pareja, ... Proceedings of the National Academy of Sciences 110 (5), 1815-1820, 2013 | 151 | 2013 |
| The landscape of somatic genetic alterations in metaplastic breast carcinomas CKY Ng, S Piscuoglio, FC Geyer, KA Burke, F Pareja, CA Eberle, RS Lim, ... Clinical cancer research 23 (14), 3859-3870, 2017 | 147 | 2017 |
| Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas FC Geyer, A Li, AD Papanastasiou, A Smith, P Selenica, KA Burke, ... Nature communications 9 (1), 1816, 2018 | 132 | 2018 |
| Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and … SK Mahil, N Wilson, N Dand, NJ Reynolds, CEM Griffiths, R Emsley, ... British Journal of Dermatology 182 (5), 1158-1166, 2020 | 119 | 2020 |
| Genetic heterogeneity in therapy-naive synchronous primary breast cancers and their metastases CKY Ng, FC Bidard, S Piscuoglio, FC Geyer, RS Lim, I de Bruijn, R Shen, ... Clinical cancer research 23 (15), 4402-4415, 2017 | 116 | 2017 |
| IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity S Chiang, B Weigelt, HC Wen, F Pareja, A Raghavendra, LG Martelotto, ... Cancer research 76 (24), 7118-7129, 2016 | 116 | 2016 |
| Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors F Pareja, AH Brandes, T Basili, P Selenica, FC Geyer, D Fan, ... Nature Communications 9 (1), 3533, 2018 | 110 | 2018 |
| The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers B Weigelt, R Bi, R Kumar, P Blecua, DL Mandelker, FC Geyer, F Pareja, ... JNCI: Journal of the National Cancer Institute 110 (9), 1030-1034, 2018 | 105 | 2018 |
| Breast intraductal papillomas without atypia in radiologic‐pathologic concordant core‐needle biopsies: rate of upgrade to carcinoma at excision F Pareja, AD Corben, SB Brennan, MP Murray, ZL Bowser, K Jakate, ... Cancer 122 (18), 2819-2827, 2016 | 102 | 2016 |
| Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression F Pareja, DA Ferraro, C Rubin, H Cohen-Dvashi, F Zhang, S Aulmann, ... Oncogene 31 (43), 4599-4608, 2012 | 99 | 2012 |
| Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing … MF Rimawi, C De Angelis, A Contreras, F Pareja, FC Geyer, KA Burke, ... Breast cancer research and treatment 167, 731-740, 2018 | 89 | 2018 |
| Ovarian cancer mutational processes drive site-specific immune evasion I Vázquez-García, F Uhlitz, N Ceglia, JLP Lim, M Wu, N Mohibullah, ... Nature 612 (7941), 778-786, 2022 | 86 | 2022 |
| MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene J Kim, FC Geyer, LG Martelotto, CKY Ng, RS Lim, P Selenica, A Li, ... The Journal of pathology 244 (2), 143-150, 2018 | 86 | 2018 |
| PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD F Pareja, D Macleod, C Shu, JF Crary, PD Canoll, AH Ross, MD Siegelin Molecular cancer research 12 (7), 987-1001, 2014 | 81 | 2014 |
| The genomic landscape of mucinous breast cancer F Pareja, JY Lee, DN Brown, S Piscuoglio, R Gularte-Mérida, P Selenica, ... JNCI: Journal of the National Cancer Institute 111 (7), 737-741, 2019 | 80 | 2019 |
| Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer N Ben-Chetrit, D Chetrit, R Russell, C Koerner, M Mancini, A Abdul-Hai, ... Science Signaling 8 (360), ra7-ra7, 2015 | 69 | 2015 |
| Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases EM da Silva, DJ Fix, APM Sebastiao, P Selenica, L Ferrando, SH Kim, ... Modern Pathology 34 (8), 1570-1587, 2021 | 65 | 2021 |
